BMEA.O (BMEA.O) News
Follow BMEA.O (BMEA.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Biomea Fusion Announces Phase 1 Results For Bmf — 650, Its Investigational Next — Generation Oral Small Molecule Glp — 1 Receptor Agonist
Oct 13 (Reuters) — Biomea Fusion, Inc.: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-generation Oral Small Molecule Glp-1 Receptor Agonist Biomea Fusion - No Severe Or Serious Adverse Eve
NEWS | Oct 13, 2026, 08:15 PM UTC
L
Biomea Fusion reports Phase 1 results for oral GLP — 1 drug BMF — 650 showing up to 3.2% weight loss at Day 29
Biomea Fusion reported Phase 1 results for oral GLP-1 drug candidate BMF-650, showing early signs of weight loss activity. Outcomes pointed to consistent short-term weight reduction versus placebo, without detailing spec
NEWS | Oct 13, 2026, 08:11 PM UTC